If the FeNO level is not raised, it is recommended that the patient be offered either a Long-Acting Muscarinic Antagonist ...

Phase 3 studies point to sustained disease control in patients who remain symptomatic despite standard therapies.

Monthly Tezepelumab injections helped 90% of severe asthma patients cut steroid use, with many seeing improved symptoms and fewer ER visits.

GSK’s depemokimab, a long-acting biologic that’s key in the British pharma’s growth plan, has won an endorsement from ...

The delivery of optimal care to individuals with bronchial asthma remains a challenge to practicing physicians. Asthma is a chronic, inflammatory condition that requires diligent long-term follow-up.

Objective Systemic corticosteroids for 5–7 days are standard care for asthma exacerbations, but the optimal duration and ...

Bronchial thermoplasty cleared by FDA but not covered by health insurance. Sept. 5, 2012— -- For Jenny McLeland, 33, of St. Louis, severe asthma restricted not only her breathing but her daily ...

Asthma is one of the most common chronic immunological diseases in humans, affecting people from childhood to old age. Progress in treating asthma has been relatively slow and treatment guidelines ...

Asthma affects approximately 23 million American children and adults, resulting in almost 15 million physician office and hospital visits, and nearly 2 million emergency department visits each year.

This Journal feature begins with a case vignette highlighting a common clinical problem. Evidence supporting various strategies is then presented, followed by a review of formal guidelines, when they ...

Urticaria updates from ACAAI 2025 include data on dupilumab for chronic urticaria, the relative effectiveness of 55 ...